{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T04:18:01Z","timestamp":1684556281897},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T00:00:00Z","timestamp":1338249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1038\/nrurol.2012.112","type":"journal-article","created":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T08:32:12Z","timestamp":1338280332000},"page":"358-360","source":"Crossref","is-referenced-by-count":1,"title":["Celecoxib trampled in the STAMPEDE trial"],"prefix":"10.1038","volume":"9","author":[{"given":"Elaine T.","family":"Lam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas W.","family":"Flaig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,29]]},"reference":[{"key":"BFnrurol2012112_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1470-2045(12)70088-8","volume":"13","author":"ND James","year":"2012","unstructured":"James, N. D.  et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol. 13, 549\u2013558 (2012).","journal-title":"Lancet Oncol."},{"key":"BFnrurol2012112_CR2","unstructured":"James, N. D. STAMPEDE. Systemic therapy in advancing or metastatic prostate cancer: evaluation of drug efficacy. A multi-arm multi-stage randomised controlled trial. STAMPEDE \n                    [online]\n                    \n                  , (2011)."},{"key":"BFnrurol2012112_CR3","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1161\/CIRCULATIONAHA.110.004671","volume":"120","author":"AM Schjerning Olsen","year":"2011","unstructured":"Schjerning Olsen, A. M.  et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 120, 2226\u20132235 (2011).","journal-title":"Circulation"},{"key":"BFnrurol2012112_CR4","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1097\/01.ju.0000107839.06670.27","volume":"171","author":"JW Basler","year":"2004","unstructured":"Basler, J. W. & Piazza, G. A. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J. Urol. 171, S59\u2013S63 (2004).","journal-title":"J. Urol."},{"key":"BFnrurol2012112_CR5","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJMoa061355","volume":"355","author":"MM Bertagnolli","year":"2006","unstructured":"Bertagnolli, M. M.  et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355, 873\u2013884 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol2012112_CR6","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1200\/JCO.2005.03.7804","volume":"24","author":"MR Smith","year":"2006","unstructured":"Smith, M. R.  et al. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and\/or radiation therapy. J. Clin. Oncol. 24, 2723\u20132728 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2012112_CR7","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","volume":"27","author":"M Hussain","year":"2009","unstructured":"Hussain, M.  et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J. Clin. Oncol. 27, 2450\u20132456 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2012112_CR8","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","volume":"24","author":"M Hussain","year":"2006","unstructured":"Hussain, M.  et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J. Clin. Oncol. 24, 3984\u20133990 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2012112_CR9","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound, C. R.  et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281, 1591\u20131597 (1999).","journal-title":"JAMA"},{"key":"BFnrurol2012112_CR10","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1200\/JCO.2005.04.7423","volume":"24","author":"UE Studer","year":"2006","unstructured":"Studer, U. E.  et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J. Clin. Oncol. 24, 1868\u20131876 (2006).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2012.112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2012.112","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2012.112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:50:22Z","timestamp":1684471822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2012.112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,29]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["BFnrurol2012112"],"URL":"https:\/\/doi.org\/10.1038\/nrurol.2012.112","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,29]]}}}